Charles Dahl, MD
Cardiovascular Disease · Orem, UTNPI 1912965344
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,580 of the $38,540 with a category attached, or 61.2%. Esperion Therapeutics, Inc. accounts for 65.0% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2021 at $17,929 and has fallen 81.9% since, to $3,243 in 2025. Among cardiovascular disease clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 812 payments — averaging $47.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$25K
- Amgen$3K
- Pfizer$2K
- Novartis$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Boehringer Ingelheim$908
- plus $5K from 37 others
Across 58 payments — averaging $1231.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$40K
- Amgen$32K
What the payments were for
- Speaking & faculty fees$23,58061%
- Travel & lodging$2,0395%
- Food & beverage$12,89333%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,540 in reported general payments places this provider in the 90th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $244,480 |
| EntrestoSacubitril/Valsartan | 117 | $140,820 |
| XareltoRivaroxaban | 54 | $73,944 |
| Repatha SureclickEvolocumab | 67 | $66,685 |
| JardianceEmpagliflozin | 24 | $27,759 |
| Rosuvastatin Calcium | 1,001 | $16,393 |
| Ezetimibe | 211 | $5,054 |
| Flecainide Acetate | 104 | $4,790 |
| Potassium Chloride | 212 | $4,453 |
| Metoprolol Succinate | 195 | $3,073 |
| Olmesartan Medoxomil | 179 | $2,933 |
| Amlodipine Besylate | 246 | $2,640 |
| Carvedilol | 189 | $2,312 |
| Metoprolol Tartrate | 146 | $1,903 |
| Metolazone | 67 | $1,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,927 | $244,480187 claims |
| NovartisEntresto | $1,605 | $140,820117 claims |
| Johnson & JohnsonXarelto | $819 | $73,94454 claims |
| Boehringer IngelheimJardiance | $908 | $27,75924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Orem
- Sean LawlessOrem$8K
- Ronald AsayOrem$8K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.